X4 Pharmaceuticals (XFOR) Gains from Investment Securities (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported Gains from Investment Securities of $205000.0 for Q4 2025, up 51.85% on a YoY basis from $135000.0 in Q4 2024, and up 34.87% quarter-over-quarter from $152000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) Gains from Investment Securities (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Gains from Investment Securities for 9 years, with the latest figure at $205000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 51.85% year-over-year to $205000.0; the trailing twelve-month figure through Dec 2025 stood at $161000.0 (down 74.8% YoY), and the FY2025 full-year result was $161000.0, down 74.8% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $205000.0, up from $152000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $24.4 million in Q2 2023, with the low at -$24.4 million in Q3 2023.
- Historically, Gains from Investment Securities has averaged $140117.6 across 5 years, with a median of $135000.0 in 2024.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities jumped 22664.81% — and 2025, when it tumbled 325.0%.
- X4 Pharmaceuticals' Gains from Investment Securities stood at $1.3 million in 2021, then slumped by 108.04% to -$108000.0 in 2022, then surged by 267.59% to $181000.0 in 2023, then fell by 25.41% to $135000.0 in 2024, then surged by 51.85% to $205000.0 in 2025.
- The last three Gains from Investment Securities figures came in at $205000.0 (Q4 2025), $152000.0 (Q3 2025), and -$369000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | X4 Pharmaceuticals | 158.81 Mn | 158.81 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 205,000.00 |
| Dec 31, 2025 | 205,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | -369,000.00 |
| Jun 30, 2025 | -369,000.00 |
| Mar 31, 2025 | 173,000.00 |
| Mar 31, 2025 | 173,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Sep 30, 2024 | 223,000.00 |
| Sep 30, 2024 | 223,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Mar 31, 2024 | 117,000.00 |
| Mar 31, 2024 | 117,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Sep 30, 2023 | -24.38 Mn |
| Sep 30, 2023 | -24.38 Mn |